CT Antigen TCR-Engineered T Cells for Myeloma

Status:
Terminated

Trial end date:
2018-04-09

Target enrollment:

Participant gender:

This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.

Phase 1/Phase 2

Adaptimmune